<DOC>
	<DOCNO>NCT02618928</DOCNO>
	<brief_summary>This study seek determine effectiveness interferon-free ABBVIE REGIMEN ± ribavirin ( RBV ) participants chronic hepatitis C ( CHC ) virus clinical practice across France .</brief_summary>
	<brief_title>The Effectiveness Paritaprevir/r - Ombitasvir , ± Dasabuvir , ± Ribavirin France</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Treatmentnaïve experience participant confirm CHC , genotype 1 4 Participants receive receive interferonfree ABBVIE REGIMEN ± RBV accord product label RBV prescribe line current local label Participant participate intend participate concurrent interventional therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>